Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer

被引:6
|
作者
Ferreira, M. R. [1 ,2 ,4 ,5 ]
Thomas, K. [2 ]
Truelove, L. [1 ,2 ]
Khan, A. [1 ,2 ]
Parker, C. [1 ,2 ]
Dearnaley, D. P. [1 ,2 ]
Gulliford, S. [1 ,3 ]
机构
[1] Inst Canc Res, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Kings Coll London, London, England
关键词
Dose-volume constraints; dosimetry; IMRT; pelvic lymph nodes; prostate cancer; gastrointestinal side-effects; SMALL-BOWEL TOXICITY; RADIATION-THERAPY; RECTAL TOXICITY; NORMAL TISSUE; VOLUME; 3D-CRT; PREDICTORS; IMRT;
D O I
10.1016/j.clon.2019.02.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations between intensity-modulated radiotherapy (IMRT) dose-volume data and long-term gastrointestinal toxicity. Materials and methods: Data from a single-centre dose-escalation trial of PLN-IMRT were analysed, including conventionally fractionated (CFRT) and hypofractionated (HFRT) radiotherapy schedules. Associations between volumes of rectum and bowel receiving specified doses and clinician- and patient-reported toxicity outcomes were investigated independently. A metric, delta median (delta M), was defined as the difference in the medians of a volume between groups with and without toxicity at a specified dose and was used to test for statistically significant differences. Results: Constraints were respected in most patients and, when exceeded, led to higher rates of gastrointestinal toxicity. Biologically relevant associations between rectum dose-points and toxicity were more numerous with both mild and moderate toxicity thresholds, but statistical significance was limited after correction for false discovery rate. Rectal V50Gy (CFRT) associated with grade 2+ bleeding; bowel V43Gy and V47 (HFRT/4 days/week schedule) associated with patient-reported loose stools and diarrhoea, respectively. Further investigation showed that CFRT patients with rectal bleeding had a mean rectal V50Gy above the treatment planning constraint. Conclusions: When dose-volume parameters are kept below tight constraints, toxicity is low. Residual dosimetry loses much of its predictive power for gastrointestinal toxicity in the setting of PLN-IMRT for prostate cancer. We have benchmarked dose-volume constraints for safely delivering PLN-IMRT using CFRT or HFRT. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd.
引用
收藏
页码:374 / 384
页数:11
相关论文
共 50 条
  • [31] Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
    Groen, Veerle H.
    Zuithoff, Nicolaas P. A.
    van Schie, Marcel
    Monninkhof, Evelyn M.
    Kunze-Busch, Martina
    de Boer, Hans C. J.
    van Zyp, Jochem van der Voort
    Pos, Floris J.
    Smeenk, Robert Jan
    Haustermans, Karin
    Isebaert, Sofie
    Draulans, Cedric
    Depuydt, Tom
    Verkooijen, Helena M.
    van der Heide, Uulke A.
    Kerkmeijer, Linda G. W.
    RADIOTHERAPY AND ONCOLOGY, 2021, 162 : 98 - 104
  • [32] Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences
    Muren, Ludvig Paul
    Wasbo, Ellen
    Helle, Svein Inge
    Hysing, Liv Bolstad
    Karlsdottir, Asa
    Odland, Odd Harald
    Valen, Harald
    Ekerold, Randj
    Johannessen, Dag Clement
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (04): : 1034 - 1041
  • [33] Pelvic lymph-node staging with18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer-the SALT trial
    Jansen, B. H. E.
    Bodar, Y. J. L.
    Zwezerijnen, G. J. C.
    Meijer, D.
    van der Voorn, J. P.
    Nieuwenhuijzen, J. A.
    Wondergem, M.
    Roeleveld, T. A.
    Boellaard, R.
    Hoekstra, O. S.
    van Moorselaar, R. J. A.
    Oprea-Lager, D. E.
    Vis, A. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (02) : 509 - 520
  • [34] OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer
    Supiot, Stephane
    Vaugier, Loig
    Pasquier, David
    Buthaud, Xavier
    Magne, Nicolas
    Peiffert, Didier
    Sargos, Paul
    Crehange, Gilles
    Pommier, Pascal
    Loos, Genevieve
    Hasbini, Ali
    Latorzeff, Igor
    Silva, Marlon
    Denis, Fabrice
    Lagrange, Jean-Leon
    Morvan, Cyrille
    Campion, Loic
    Blanc-Lapierre, Audrey
    EUROPEAN UROLOGY, 2021, 80 (04) : 405 - 414
  • [35] Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial
    Schilham, Melline G. M.
    Somford, Diederik M.
    Kusters-Vandevelde, Heidi V. N.
    Hermsen, Rick
    van Basten, Jean Paul A.
    Hoekstra, Robert J.
    Scheenen, Tom W. J.
    Gotthardt, Martin
    Sedelaar, J. P. Michiel
    Rijpkema, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (03) : 423 - 429
  • [36] PHASE II TRIAL OF NEOADJUVANT BEVACIZUMAB, CAPECITABINE, AND RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER
    Crane, Christopher H.
    Eng, Cathy
    Feig, Barry W.
    Das, Prajnan
    Skibber, John M.
    Chang, George J.
    Wolff, Robert A.
    Krishnan, Sunil
    Hamilton, Stanley
    Janjan, Nora A.
    Maru, Dipen M.
    Ellis, Lee M.
    Rodriguez-Bigas, Miguel A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 824 - 830
  • [37] Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study
    Bjoreland, Ulrika
    Notstam, Kristina
    Fransson, Per
    Soderkvist, Karin
    Beckman, Lars
    Jonsson, Joakim
    Nyholm, Tufve
    Widmark, Anders
    Karlsson, Camilla Thellenberg
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [38] Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases
    Lunger, Lukas
    Steinhelfer, Lisa
    Korn, Philipp
    Eiber, Matthias
    Maurer, Tobias
    Buechler, Jakob
    Horn, Thomas
    Gschwend, Jurgen E.
    Heck, Matthias M.
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (01): : 95 - 98
  • [39] Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients
    Onal, Cem
    Ozyigit, Gokhan
    Guler, Ozan Cem
    Hurmuz, Pervin
    Torun, Nese
    Tuncel, Murat
    Dolek, Yemliha
    Yedekci, Yagiz
    Oymak, Ezgi
    Tilki, Burak
    Akyol, Fadil
    RADIOTHERAPY AND ONCOLOGY, 2020, 151 : 222 - 227
  • [40] Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer
    Gandaglia, Giorgio
    De Lorenzis, Elisa
    Novara, Giacomo
    Fossati, Nicola
    De Groote, Ruben
    Dovey, Zach
    Suardi, Nazareno
    Montorsi, Francesco
    Briganti, Alberto
    Rocco, Bernardo
    Mottrie, Alexandre
    EUROPEAN UROLOGY, 2017, 71 (02) : 249 - 256